ReviewJAMA oncology2023

Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.

Ciara Catherine O'Sullivan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.